Journal
EPIGENOMICS
Volume 8, Issue 8, Pages 1079-1085Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2016-0035
Keywords
EDVs; malignant pleural mesothelioma; mesomiR-1; miRNA; miR-16; targeted delivery
Categories
Funding
- Translational Program Grant from Cancer Institute NSW [11TPG3-06]
- Cancer Council NSW [RG14-17]
Ask authors/readers for more resources
miRNAs are responsible for post-transcriptional control of gene expression, and are frequently downregulated in cancer. It has become well established that restoring miRNA levels can inhibit tumor growth, and many studies have demonstrated this in preclinical models. This in turn has led to the first clinical trials of miRNA replacement therapy. This special report focuses on the development of TargomiRs-miRNA mimics delivered by targeted bacterial minicells-and the very first clinical experience of a miRNA replacement therapy in thoracic cancer patients in the Phase I MesomiR-1 trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available